Sold for research use only (RUO)
The discovery is exciting because it suggests appetite suppression may be possible without the gastrointestinal and muscle-loss costs of current GLP-1 agonists, but the human translation has not yet happened
GLP-1 works by increasing the feeling of fullness and decreasing appetite
L-glutathione is the active, naturally occurring form of glutathione
Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the KrasG12D mouse model
constipation, reflux, or intermittent nausea may continue Persistent or progressive symptoms rather than gradual improvement After month 3 Symptoms may remain mild or infrequent at a tolerated regimen New severe symptoms should not automatically be blamed on the medication The most important pattern is not simply "week 1 is bad and month 3 is good." A more accurate pattern is initiation, adaptation, possible symptom flare during dose escalation, and reassessment based on tolerability